AL-TNBC-01

Avavilable at 13 locations

TENACITY: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer

STAR 14059

Avavilable at 1 location

Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

USOR 17079

Avavilable at 7 locations

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

USOR 17188

Avavilable at 6 locations

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

USOR 17194

Avavilable at 1 location

A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination with Palbociclib in Women With Advanced or Metastatic ER- Positive and HER2-Negative Breast Cancer

USOR 19054

Avavilable at 15 locations

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer

USOR 19105

Avavilable at 15 locations

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Gdc-0077 Plus Palbociclib And Fulvestrant Versus Placebo Plus Palbociclib And Fulvestrant In Patients With Pik3ca-Mutant, Horomone Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer

USOR 19226

Avavilable at 15 locations

A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

USOR 20210

Avavilable at 12 locations

Breast Cancer Index (BCI) Registry Study

USOR 20431

Avavilable at 4 locations

A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology